Seqanswers Leaderboard Ad

Collapse

Announcement

Collapse
No announcement yet.

Revio from Pacific Biosciences: Latest Sequencing Technologies—Part 3

Collapse
X
Collapse
  •  

  • Revio from Pacific Biosciences: Latest Sequencing Technologies—Part 3

    Pacific Biosciences (PacBio) revealed two new sequencers during this year’s American Society of Human Genetics meeting. The first instrument, Revio, which will be covered in this article, is a significant upgrade from their previous Sequel II device. It has lower costs, shorter run times, more SMRT Cells and zero-mode waveguides (ZMW), and significantly higher output compared to PacBio’s other sequencers.
    Click image for larger version  Name:	img_revio_right_closed_rfl.png Views:	0 Size:	127.3 KB ID:	323394
    Image of Revio (courtesy of PacBio)


    Read type and length
    As a part of PacBio’s long-read sequencing systems, Revio was designed to perform their signature High Fidelity (HiFi) sequencing. The read lengths can vary from 15–18 kb with a read accuracy of 99.95% (Q33).

    Flow cell/SMRT Cell options
    Revio supports 4 high-density SMRT Cells that can be run in parallel or independently. Each SMRT Cell contains 25 million ZMWs and the run times have been reduced to 24 hours. This is a significant increase from the Sequel IIe, which ran a single SMRT Cell that only supported 8 million ZMWs for a 30-hour sequencing run. The upgrades in SMRT Cells, ZMWs, and run times account for a 15x increase in data generation.

    Data output
    The data output of Revio is up to 90 Gb per SMRT Cell or a total of 360 Gb of HiFi reads per day. Annual outputs are estimated for 1,300 Revio SMRT Cells per year: the equivalent of 1,300 human genomes at 30X coverage. HiFi reads are outputted in BAM format, and the output files are greatly reduced in size (by 50% per base) despite the increase in data generation.

    Analysis options
    Revio comes equipped with NVIDIA GPUs for a >20x higher computing power than their previous instruments. Demultiplexing is completed on the sequencer as well as direct methylation calling. In addition, Google teamed up with PacBio to produce Google Health DeepConsensus, which has been included in the instrument. Google Health DeepConsensus uses deep-learning technology to correct for errors during sequencing and leads to an increased data yield and base calling accuracy1.

    Common applications
    • Variant calling (SNVs, indels, SVs)
    • Whole genome sequencing
    • Single-cell transcriptomics
    • Large gene panels
    • 5mC at CpG sites

    Release date
    PacBio is already taking orders for Revio and shipments are expected to begin in the first quarter of 2023.

    Highlights
    • Shorter run times with significantly increased (15x) data output and an increased HiFi read throughput
    • Easier setup and flexibility—no nitrogen is required, there are fewer consumables, and runs can be queued during sequencing.
    • Long HiFi reads (>10 kb) can be used to resolve small variants, structural variants, and repeat expansions while providing uniform coverage
    • An estimated $1,000 complete, phased genome
    • Enhanced Google Health DeepConsensus algorithms decrease basecalling errors and increase data yields.

    References
    1. Baid, G., et al. (2022). DeepConsensus improves the accuracy of sequences with a gap-aware sequence transformer. Nature Biotechnology, 1-7.

    To compare sequencing technologies please visit Biocompare
      Please sign into your account to post comments.

    About the Author

    Collapse

    seqadmin Benjamin Atha holds a B.A. in biology from Hood College and an M.S. in biological sciences from Towson University. With over 9 years of hands-on laboratory experience, he's well-versed in next-generation sequencing systems. Ben is currently the editor for SEQanswers. Find out more about seqadmin

    Latest Articles

    Collapse

    • Current Approaches to Protein Sequencing
      by seqadmin


      Proteins are often described as the workhorses of the cell, and identifying their sequences is key to understanding their role in biological processes and disease. Currently, the most common technique used to determine protein sequences is mass spectrometry. While still a valuable tool, mass spectrometry faces several limitations and requires a highly experienced scientist familiar with the equipment to operate it. Additionally, other proteomic methods, like affinity assays, are constrained...
      04-04-2024, 04:25 PM
    • Strategies for Sequencing Challenging Samples
      by seqadmin


      Despite advancements in sequencing platforms and related sample preparation technologies, certain sample types continue to present significant challenges that can compromise sequencing results. Pedro Echave, Senior Manager of the Global Business Segment at Revvity, explained that the success of a sequencing experiment ultimately depends on the amount and integrity of the nucleic acid template (RNA or DNA) obtained from a sample. “The better the quality of the nucleic acid isolated...
      03-22-2024, 06:39 AM
    • Techniques and Challenges in Conservation Genomics
      by seqadmin



      The field of conservation genomics centers on applying genomics technologies in support of conservation efforts and the preservation of biodiversity. This article features interviews with two researchers who showcase their innovative work and highlight the current state and future of conservation genomics.

      Avian Conservation
      Matthew DeSaix, a recent doctoral graduate from Kristen Ruegg’s lab at The University of Colorado, shared that most of his research...
      03-08-2024, 10:41 AM

    ad_right_rmr

    Collapse

    News

    Collapse

    Working...
    X